Lipanthyl Micronised

Fenofibrate, the active ingredient in Lipanthyl Micronised, is a fibrate presented as a micronised oral tablet for oral use. It is indicated for the management of hypertriglyceridemia and mixed dyslipidemia in adult patients.

GNH USA supplies Lipanthyl Micronised as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU marketing authorisation standards and is manufactured under GMP conditions, ensuring consistent potency and safety for global distribution. Our supply chain includes temperature‑controlled logistics and regulatory support for import clearance.

Lipanthyl Micronised (fenofibrate) is used to modify lipid metabolism in patients with elevated triglyceride levels. - Hypertriglyceridemia: reduces plasma triglyceride concentrations. - Mixed dyslipidemia: lowers triglycerides and modestly raises HDL‑cholesterol. - Primary hypercholesterolemia (as adjunct therapy): improves overall lipid profile when used with other lipid‑lowering agents.

Fenofibrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in ALT/AST. - Muscle pain: mild myalgia without weakness. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with risk of renal failure. - Severe liver injury: hepatitis or hepatic failure. - Acute pancreatitis: inflammation of the pancreas. - Myopathy: muscle weakness with elevated CK. - Anaphylactic reactions: severe allergic response. - Blood dyscrasias: neutropenia or thrombocytopenia.

Before initiating therapy, clinicians should consider several safety aspects. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Renal function assessment: adjust use in patients with impaired clearance. - Gallstone risk: evaluate history of biliary disease. - Hypothyroidism caution: monitor thyroid status as risk of myopathy may increase. - Severe renal impairment: avoid or use only under specialist supervision. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Fenofibrate can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy and rhabdomyolysis. - Cyclosporine: may elevate fenofibrate plasma levels, enhancing toxicity. - High‑dose statins (e.g., rosuvastatin): increase risk of severe muscle injury.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate may potentiate anticoagulant effect, requiring INR monitoring. - Oral hypoglycemics: may enhance glucose‑lowering effect, risk of hypoglycemia. - ACE inhibitors: potential for increased serum creatinine; monitor renal function.